1. Home
  2. STTK vs OPTX Comparison

STTK vs OPTX Comparison

Compare STTK & OPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • OPTX
  • Stock Information
  • Founded
  • STTK 2016
  • OPTX 1981
  • Country
  • STTK United States
  • OPTX United States
  • Employees
  • STTK N/A
  • OPTX N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • OPTX Blank Checks
  • Sector
  • STTK Health Care
  • OPTX Finance
  • Exchange
  • STTK Nasdaq
  • OPTX Nasdaq
  • Market Cap
  • STTK 112.6M
  • OPTX 98.6M
  • IPO Year
  • STTK 2020
  • OPTX N/A
  • Fundamental
  • Price
  • STTK $1.96
  • OPTX $2.15
  • Analyst Decision
  • STTK Hold
  • OPTX
  • Analyst Count
  • STTK 5
  • OPTX 0
  • Target Price
  • STTK $3.00
  • OPTX N/A
  • AVG Volume (30 Days)
  • STTK 162.8K
  • OPTX 170.1K
  • Earning Date
  • STTK 11-06-2025
  • OPTX 11-14-2025
  • Dividend Yield
  • STTK N/A
  • OPTX N/A
  • EPS Growth
  • STTK N/A
  • OPTX N/A
  • EPS
  • STTK N/A
  • OPTX N/A
  • Revenue
  • STTK $1,000,000.00
  • OPTX $28,816,530.00
  • Revenue This Year
  • STTK N/A
  • OPTX N/A
  • Revenue Next Year
  • STTK N/A
  • OPTX N/A
  • P/E Ratio
  • STTK N/A
  • OPTX N/A
  • Revenue Growth
  • STTK N/A
  • OPTX 2.45
  • 52 Week Low
  • STTK $0.69
  • OPTX $0.85
  • 52 Week High
  • STTK $2.71
  • OPTX $5.10
  • Technical
  • Relative Strength Index (RSI)
  • STTK 49.33
  • OPTX 45.79
  • Support Level
  • STTK $1.86
  • OPTX $2.04
  • Resistance Level
  • STTK $2.06
  • OPTX $2.34
  • Average True Range (ATR)
  • STTK 0.14
  • OPTX 0.26
  • MACD
  • STTK -0.00
  • OPTX -0.09
  • Stochastic Oscillator
  • STTK 43.64
  • OPTX 11.65

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About OPTX Syntec Optics Holdings Inc.

Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining.

Share on Social Networks: